Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.

AIM Nanoneuroscience, based on the use polymeric nanoparticles (NPs), represents an emerging field of research for achieving an effective therapy for neurodegenerative diseases. In particular, poly-lactide-co-glycolide (PLGA) glyco-heptapetide-conjugated NPs (g7-NPs) were shown to be able to cross the blood-brain barrier (BBB). However, the in vivo mechanisms of the BBB crossing of this kind of NP has not been investigated until now. This article aimed to develop a deep understanding of the mechanism of BBB crossing of the modified NPs. MATERIALS & METHODS Loperamide and rhodamine-123 (model drugs unable to cross the BBB) were loaded into NPs, composed of a mixture of PLGA, differently modified with g7 or with a random sequence of the same aminoamids (random-g7). To study brain targeting of these model drugs, loaded NPs were administered via the tail vein in rats in order to perform both pharmacological studies and biodistribution analysis along with fluorescent, confocal and electron microscopy analysis, in order to achieve the NP BBB crossing mechanism. Computational analysis on the conformation of the g7- and random-g7-NPs of the NP surface was also developed. RESULTS Only loperamide delivered to the brain with g7-NPs created a high central analgesia, corresponding to the 14% of the injected dose, and data were confirmed by biodistribution studies. Electron photomicrographs showed the ability of g7-NPs in crossing the BBB as evidenced by several endocytotic vesicles and macropinocytotic processes. The computational analysis on g7 and random-g7 showed a different conformation (linear vs globular), thus suggesting a different interaction with the BBB. CONCLUSION Taken together, this evidence suggested that g7-NP BBB crossing is enabled by multiple pathways, mainly membrane-membrane interaction and macropinocytosis-like mechanisms. The results of the computational analysis showed the Biousian structure of the g7 peptide, in contrast to random-g7 peptide (globular conformation), suggesting that this difference is pivotal in explaining the BBB crossing and allowing us to hypothesize regarding the mechanism of BBB crossing by g7-NPs.

[1]  G. Vassal,et al.  Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.

[2]  V. Torchilin,et al.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Reynolds.  THE USE OF LEAD CITRATE AT HIGH pH AS AN ELECTRON-OPAQUE STAIN IN ELECTRON MICROSCOPY , 1963, The Journal of cell biology.

[4]  G. Tosi,et al.  Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. , 2005, Biomaterials.

[5]  G. Tosi,et al.  Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[6]  M. Gumbleton,et al.  Endocytosis at the blood–brain barrier: From basic understanding to drug delivery strategies , 2006, Journal of drug targeting.

[7]  L. Pauling,et al.  The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. , 1951, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Grimme,et al.  Molecular Electrostatic Potentials: Concepts and Applications , 1998 .

[9]  P. Couraud,et al.  How do extracellular pathogens cross the blood-brain barrier? , 2002, Trends in microbiology.

[10]  Maria Angela Vandelli,et al.  Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures. , 2006, Biomaterials.

[11]  G. Tosi,et al.  Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[12]  A. R. Srinivasan,et al.  Modulation of nucleic acid structure by ligand binding: induction of a DNA.RNA.DNA hybrid triplex by DAPI intercalation. , 1997, Bioorganic & medicinal chemistry.

[13]  Wei-Chiang Shen,et al.  Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives , 2007, Pharmaceutical Research.

[14]  I. Alves,et al.  Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers. , 2005, Journal of the American Chemical Society.

[15]  Harvey T. McMahon,et al.  Membrane curvature and mechanisms of dynamic cell membrane remodelling , 2005, Nature.

[16]  Michael M. Kozlov,et al.  How proteins produce cellular membrane curvature , 2006, Nature Reviews Molecular Cell Biology.

[17]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[18]  N. Prasadarao,et al.  Outer membrane protein A of Escherichia coli contributes to invasion of brain microvascular endothelial cells , 1996, Infection and immunity.

[19]  P. Couraud,et al.  Meningococcal Type IV Pili Recruit the Polarity Complex to Cross the Brain Endothelium , 2009, Science.

[20]  Michael M Palian,et al.  Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. , 2003, Journal of the American Chemical Society.

[21]  W. Pardridge.  Why is the global CNS pharmaceutical market so under-penetrated? , 2002, Drug discovery today.

[22]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[23]  B. Ruozi,et al.  Chapter 3 - Colloidal systems for CNS drug delivery. , 2009, Progress in brain research.

[24]  Hatem Fessi,et al.  Nanocapsule formation by interfacial polymer deposition following solvent displacement , 1989 .

[25]  M. Dhanasekaran,et al.  Glycosylated neuropeptides: A new vista for neuropsychopharmacology? , 2005, Medicinal research reviews.

[26]  R. Mumper,et al.  In Situ Blood–Brain Barrier Transport of Nanoparticles , 2003, Pharmaceutical Research.

[27]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[28]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[29]  M A Vandelli,et al.  Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[30]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[31]  N. B. Eddy,et al.  Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. , 1953, The Journal of pharmacology and experimental therapeutics.

[32]  M A Vandelli,et al.  Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[34]  Barbara Ruozi,et al.  Polymeric nanoparticles for the drug delivery to the central nervous system , 2008, Expert opinion on drug delivery.